Geoffrey Cox - Atea PharmaceuticalsI Independent Director
| AVIR Stock | USD 3.67 0.05 1.34% |
Director
Dr. Geoffrey F. Cox, Ph.D. is Independent Director of the Company. He is currently the interim Chief Executive Officer of QLT Inc., an ophthalmology company based in Vancouver, BC, and a Director . Dr. Cox has extensive pharmaceutical and biotechnology experience holding a broad range of senior management and board positions with private and public companies. Dr. Cox remains the Principal of Beacon Street Advisors LLC which provides corporate, operational and organizational strategic advice and interim management support to life sciences companies, but is working full time for QLT at this time. Previously, he was a partner with Red Sky Partners LLC, a life sciences consulting firm . He also served as a Director of Gallus Biopharmaceuticals LLC, a biologics contract manufacturing and development company, and currently serves as a Director of LakewoodAmedex LLC, a company developing novel antibiotics and RNA silencing technology. Dr. Cox was Chairman, President and CEO of GTC Biotherapeutics Inc., a company focused on the development of recombinant therapeutic proteins, including proteins for the treatment of rare diseases, using transgenic animal production technology. Prior to 2001, Dr. Cox is a past Chairman and current member of the Board of the Massachusetts Biotechnology Council. He previously served on the Board of Biotechnology Industries Association and as a member of its Health Governing and Emerging Companies Sections since 2012.
| Age | 71 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Address | 225 Franklin Street, Boston, MA, United States, 02110 |
| Phone | 857 284 8891 |
| Web | https://ateapharma.com |
Atea PharmaceuticalsI Management Efficiency
The company has return on total asset (ROA) of (0.1189) % which means that it has lost $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2274) %, meaning that it created substantial loss on money invested by shareholders. Atea PharmaceuticalsI's management efficiency ratios could be used to measure how well Atea PharmaceuticalsI manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/23/2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Atea PharmaceuticalsI's Non Current Assets Total are relatively stable compared to the past year. As of 04/23/2024, Non Currrent Assets Other is likely to grow to about 1.5 M, while Net Tangible Assets are likely to drop slightly above 398.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Lynda Reid | Evotec SE ADR | N/A | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Norah Barlow | Evotec SE ADR | N/A | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| David Anstice | Alkermes Plc | 69 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Hamish Stevens | Evotec SE ADR | N/A | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Grainne Troute | Evotec SE ADR | N/A | |
| Robert Breyer | Alkermes Plc | 73 | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Anthony Quirk | Evotec SE ADR | N/A | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.12 |
Atea PharmaceuticalsInc Leadership Team
Elected by the shareholders, the Atea PharmaceuticalsI's board of directors comprises two types of representatives: Atea PharmaceuticalsI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atea. The board's role is to monitor Atea PharmaceuticalsI's management team and ensure that shareholders' interests are well served. Atea PharmaceuticalsI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atea PharmaceuticalsI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Exec Officer | ||
| XiaoJian Zhou, Executive Development | ||
| Jayanthi Wolf, Executive Affairs | ||
| Wayne CPA, Executive Officer | ||
| Anne VanLent, Independent Director | ||
| Ariyapadi Krishnaraj, Vice Marketing | ||
| Mark Colonnese, CFO, Executive Vice President | ||
| Russell Plumb, Executive Chairman of the Board | ||
| JeanPierre Sommadossi, Chairman, Founder | ||
| John Vavricka, Chief Officer | ||
| Geoffrey Cox, Independent Director | ||
| Nancy Agrawal, Executive Development | ||
| Maria MD, Chief Officer | ||
| John Richard, Independent Director | ||
| Jonae Barnes, Senior Communications | ||
| Andrea JD, Executive CFO | ||
| Michael Dunne, Independent Director | ||
| Keith Pietropaolo, Senior Sciences | ||
| Joseph Patti, President CEO, Director | ||
| Adel Moussa, Executive Chemistry | ||
| Armando Anido, Independent Director | ||
| Michael Dougherty, Independent Director |
Atea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atea PharmaceuticalsI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | (266.82 M) | ||||
| Shares Outstanding | 84.16 M | ||||
| Shares Owned By Insiders | 9.46 % | ||||
| Shares Owned By Institutions | 67.55 % | ||||
| Number Of Shares Shorted | 1.67 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 1.90 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Atea PharmaceuticalsI in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Atea PharmaceuticalsI's short interest history, or implied volatility extrapolated from Atea PharmaceuticalsI options trading.
Pair Trading with Atea PharmaceuticalsI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
| 0.73 | EGRX | Eagle Pharmaceuticals | PairCorr |
Moving against Atea Stock
| 0.54 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.5 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.47 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Atea PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea PharmaceuticalsInc to buy it.
The correlation of Atea PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.63) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.12) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.